Phase I-II Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Conditions

Anus | Breast - Female | Breast - Male | Colon | Esophagus | Hodgkin's Lymphoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Unknown Sites | Urinary Bladder

Phase I-II

What is the purpose of this trial?

Primary Objectives

Phase 1: To assess safety, and to identify the maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX660.

Phase 2: To assess preliminary efficacy, as determined by response rate in certain tumor types.

Secondary Objectives

  • To determine the pharmacokinetic (PK) parameters of orally administered ASTX660 in humans.
  • To evaluate other efficacy parameters, such as duration of response and progression-free survival.
  • To evaluate relevant pharmacodynamic (PD) targets and potential biomarkers of ASTX660 activity.
  • Trial with
    Astex Pharmaceuticals, Inc.
  • Start Date
    04/14/2016
  • End Date
    06/30/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Laura Leary

  • Last Updated
    10/09/2018
  • Study HIC
    #1505015798